A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study in Healthy Participants and Multiple Dose Study in Participants With Ulcerative Colitis to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-66525433
Latest Information Update: 18 Jan 2022
At a glance
- Drugs JNJ 66525433 (Primary)
- Indications Inflammatory bowel diseases; Ulcerative colitis
- Focus Adverse reactions
- Sponsors Janssen Research & Development
- 29 Dec 2021 Status changed from recruiting to discontinued. Reason the study was stopped: Sponsor Decision.
- 29 Apr 2021 Planned End Date changed from 24 Oct 2022 to 11 Jun 2023.
- 18 Dec 2020 Planned number of patients changed from 128 to 140.